Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 773-778, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rexin, M.
Right arrow Articles by Feussner, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rexin, M.
Right arrow Articles by Feussner, G.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 1998;44:773-778.)
© 1998 American Association for Clinical Chemistry, Inc.

Lipids and Lipoproteins

A competitive reverse transcription–PCR to study apolipoprotein {epsilon} gene expression

Martin Rexin, and Giso Feussnera

Department of Internal Medicine I, University of Heidelberg, Endocrinology and Metabolism, Bergheimer Strasse 58, D-69115 Heidelberg, Germany.
a Address correspondence to this author at: Medizinische Universitätsklinik Heidelberg, Abteilung Innere Medizin I, Endokrinologie und Stoffwechsel, Bergheimer Strasse 58, D-69115 Heidelberg. Fax 49 6221 56 53 42; e-mail uk691jd{at}genius.embnet.dkfz-heidelberg.de.

We developed a rapid and simple competitive reverse transcription-polymerase chain reaction for the quantification of apo{epsilon} mRNA in human monocyte-derived macrophages. The method was applied, and its reliability was shown in patients with the familial lipoprotein disorder, type III hyperlipoproteinemia. Type III hyperlipoproteinemic patients express markedly higher concentrations of apo{epsilon} mRNA when compared with healthy controls. Patients with this disease are usually (>90%) homozygous for a receptor binding-defective isoform of apolipoprotein apo E (apo E2). The higher expression of apo{epsilon} mRNA in the patients could, therefore, be a physiological mechanism to compensate for functionally defective apo E. The developed procedure might be valuable in assessment of apo{epsilon} gene expression in human disease.




The following articles in journals at HighWire Press have cited this article:


Home page
 Scand J Public HealthHome page
M. L. Masemola, M. Alberts, and P. Urdal
Apolipoprotein E genotypes and their relation to lipid levels in a rural South African population 1
Scand J Public Health, August 1, 2007; 35(69_suppl): 60 - 65.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. E. Thorngate, L. L. Rudel, R. L. Walzem, and D. L. Williams
Low Levels of Extrahepatic Nonmacrophage ApoE Inhibit Atherosclerosis Without Correcting Hypercholesterolemia in ApoE-Deficient Mice
Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1939 - 1945.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.